Paloxi

Quick links to important sections

Paloxi

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paloxi

What is Paloxi? An Overview

The following information establishes the core identity and pharmacological classification of the synthetic drug Palonosetron, which is marketed under the trade name Paloxi.

Property Description
Active Ingredient Palonosetron Hydrochloride
Form Intravenous (IV) Solution, Oral Capsule
Pharmacological Class Selective Serotonin 5-HT3 Receptor Antagonist
Common Use Prevention of Nausea and Vomiting
Origin Synthetic Compound

What is the Drug Palonosetron and What Does It Do?

Paloxi refers to the medication whose active substance is Palonosetron Hydrochloride (INN: Palonosetron). This drug is a synthetic compound classified as an antiemetic medicine, designed to help prevent and control nausea and vomiting. It is considered a second-generation agent in its therapeutic class, clinically recognized for its sustained antiemetic efficacy compared to older counterparts.

The pharmacological class of Palonosetron is the selective Serotonin 5-HT3 receptor antagonist. This classification means the drug works by blocking the activity of the 5-HT3 receptor, a chemical sensor that responds to the neurotransmitter serotonin. By disrupting these signals, Palonosetron prevents the activation of the brain’s Chemoreceptor Trigger Zone. The drug is indicated for the prevention of acute and delayed nausea and vomiting.


Palonosetron: Form and Classification Type

Palonosetron is provided as a single-ingredient product in established pharmaceutical preparations for systemic use. It is available as a ready-to-use Intravenous (IV) solution for injection and in the form of an oral capsule.

Palonosetron is characterized as an agent with a prolonged duration of action. This structural distinction underscores the drug's extended efficacy in controlling the emetic reflex. The availability of both the parenteral (IV) and oral forms provides flexibility in administering the active ingredient, ensuring the medication can be used reliably in various clinical scenarios.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Paloxi?

Possible Side Effects and Safety Information for Paloxi (Palonosetron)

The official safety profile for Palonosetron is structured around the adverse reactions documented in clinical trials and post-marketing surveillance, classified by frequency and affected organ systems. The primary safety concerns are categorized as follows:

Frequency-Classified Adverse Reactions

The regulatory documents classify side effects based on how often they are expected to occur:

  • Common Reactions (ge 1/100 to < 1/10): Headache, Constipation, Diarrhoea, Dizziness, Dyspepsia, and Fatigue are frequently listed in regulatory documents.
  • Uncommon Reactions (ge 1/1,000 to < 1/100): These include reports of cardiac conduction issues such as Electrocardiogram QT prolonged and Bradycardia, as well as neurological events like somnolence or paraesthesia, and elevated liver transaminases.

Serious Adverse Reactions and Restrictions

Certain high-level safety concerns are explicitly documented in official prescribing information:

  • Serotonin Syndrome is a serious risk noted when Palonosetron, a 5-HT3 receptor antagonist, is used concomitantly with other serotonergic medicines (e.g., SSRIs, SNRIs). This risk is associated with potentially severe changes in mental status and autonomic function.
  • Hypersensitivity: The drug is contraindicated in patients with a known hypersensitivity to Palonosetron. Documented serious reactions include Anaphylaxis and anaphylactic shock.
  • Gastrointestinal Risk: Post-marketing reports have included cases of severe constipation leading to Faecal Impaction requiring hospitalisation.

Population-Specific Safety Considerations

Official documents note that caution is required for patients with pre-existing risk factors for QT prolongation (e.g., personal history, electrolyte abnormalities, or use of other QT-prolonging medicines). Furthermore, safety data advises that breast-feeding should be discontinued during therapy, and monitoring is specified for individuals with a history of constipation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents from health authorities define the overdose profile for Palonosetron (the active ingredient in Paloxi) by documenting specific clinical manifestations and the required immediate emergency actions.

Overdosage may be associated with high-risk neurological and respiratory symptoms. Documented signs of potential overexposure include seizures, fainting (syncope), difficulty breathing, pale or blue-colored skin, and loss of consciousness (coma). Furthermore, as with other drugs in its class, there is a risk of developing Serotonin Syndrome, which requires monitoring for changes in mental status, heart rate, and muscle function, as described in official prescribing information.

Action Required by Regulator Circumstance Mandating Action
Call emergency services (911) immediately If the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened (coma).
Call the poison control helpline For guidance in any case of suspected overdosage.

Overdose Management: Regulatory labeling explicitly states that there is no known specific antidote to Palonosetron. Therefore, an overdose must be managed with supportive care focused on the patient's symptoms. Due to the drug’s large volume of distribution in the body, health authorities note that dialysis is unlikely to be an effective treatment for overdosage.

Therapeutic Uses of Paloxi

What Paloxi Treats: Main Uses and Benefits

The core function of Paloxi (Palonosetron) is to provide prophylactic antiemetic support, meaning it is commonly used to prevent the onset of severe sickness rather than addressing existing mild symptoms. It may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns. The medication is commonly used in two main areas: prevention of nausea and vomiting associated with chemotherapy (CINV) and prevention of postoperative nausea and vomiting (PONV).

The medication is relevant in contexts involving heightened systemic burden where the prevention of nausea and vomiting is necessary. This medication is commonly used across oncology patients to prevent the distressing nausea and vomiting that arises from chemotherapy, and in surgical contexts to manage sickness following general anesthesia. Paloxi provides support against symptoms that may appear suddenly or fluctuate by addressing both the acute emesis (sickness occurring within 24 hours) and the delayed emesis (sickness occurring 24 hours or more after treatment). This helps manage symptom intensity over several days and **supports the patient during difficult episodes by easing distress.


Quick Fact: Relief for Acute and Delayed Sickness

  • Primary Application: Applied across domains where additional symptomatic support is needed, particularly in oncology and surgical recovery.
  • Symptom Focus: Helps manage symptom clusters that may become intense or disruptive, including acute nausea, delayed emesis, and post-anesthesia sickness.
  • Key Benefit: Supports general well-being during symptomatic phases by providing support that helps ease the overall symptom burden during symptomatic phases of extended duration.

Regulatory References

  1. NIH DailyMed official prescribing information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Paloxi — Official Regulatory Information

The eligibility profile for Paloxi (Palonosetron) is defined by official governmental regulatory documents, establishing specific rules for patient populations.

Category Eligibility Rule (Based on Regulatory Labeling)
Contraindicated Populations Patients with known hypersensitivity to Palonosetron or any of its components.
Age-Group Eligibility Adults (17 years and older) are approved for use.
Pediatric Limitations Safety is not established in neonates (less than 1 month) or for Postoperative Nausea and Vomiting (PONV) in patients under 18 years.
Organ Function Use is allowed in patients with renal or hepatic impairment; no dose adjustment is necessary.
Pregnancy and Lactation Use is not recommended in pregnancy, and breastfeeding should be discontinued during therapy.

The regulatory documents indicate that Paloxi is approved for adults and conditionally for pediatric patients aged 1 month to 17 years for acute chemotherapy-induced nausea and vomiting (CINV). Beyond hypersensitivity, other limitations include a requirement for caution and monitoring in patients with cardiac abnormalities or those prone to severe constipation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Palonosetron (Paloxi) as defined in government regulatory labeling.


Interaction Scope

Category Regulatory Statement
Medicinal product categories with documented interactions Serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs)
Specific interacting medicines (if explicitly listed) Dexamethasone, Aprepitant, Metoclopramide, Fentanyl, Lithium, Tramadol, Mirtazapine, intravenous Methylene Blue
Mechanistic basis of interactions Pharmacodynamic interaction (additive effects leading to Serotonin Syndrome risk); No clinically significant pharmacokinetic interactions with CYP enzyme inhibition/induction
Timing-based interaction rules The IV solution must be administered via a line that is flushed with normal saline before and after administration
Interaction-related restrictions Palonosetron IV solution must not be mixed with other drugs

Official Interaction Profile

Regulatory documents establish that the drug's primary interaction concern is pharmacodynamic, centered on the potential risk of Serotonin Syndrome when Palonosetron is co-administered with other serotonergic agents. The FDA and EMA labels categorize this as a use with caution interaction, not a formal contraindication. Palonosetron is documented to be primarily metabolized by CYP2D6 but is not an inhibitor or inducer of major CYP enzymes, confirming it is not expected to significantly alter the clearance of many co-administered medications. Accordingly, co-administration with frequently used agents such as Dexamethasone or Metoclopramide resulted in no significant pharmacokinetic drug interactions. Furthermore, the bioavailability of the oral capsule is independent of food intake.

Mechanism of Action

How Paloxi Works: Mechanism of Action

Palonosetron's mechanism is defined by its action as a selective antagonist of the Serotonin 5- HT3 Receptor. This receptor is a ligand-gated ion channel whose activation is typically triggered by the neurotransmitter serotonin (5- HT). The molecule exhibits high binding affinity and a notably slow dissociation rate, which results in a persistent functional silence of the receptor.

This binding action occurs simultaneously in two key locations: peripherally on vagal afferent nerve terminals in the gastrointestinal (GI) tract and centrally within the Chemoreceptor Trigger Zone (CTZ) of the brainstem. By blocking the 5- HT3 receptors at these sites, Palonosetron effectively interrupts the neural cascade that transmits excitatory signals to the Vomiting Center. This integrated central and peripheral blockade achieves a comprehensive functional blockade of the serotonergic component of the reflex pathway.

The mechanism is highly specific to the serotonergic system. This constraint means the blockade does not modulate the reflex when it is driven by non-serotonergic mediators, such as Substance P, which utilizes the Neurokinin-1 (NK1) receptor pathway.

Dosage and Administration Information

How to use Paloxi (Palonosetron) — General Administration Guidelines

Paloxi is administered as a single dose by a healthcare professional, either through Intravenous (IV) injection/infusion or as an Oral capsule.

Dosing and Timing

Administration must occur prior to the medical procedure.

Patient Group Route & Dose Administration Timing & Rate
Adults (Chemotherapy) IV: 0.25 mg or Oral: 0.5 mg IV: Infused over 30 seconds approx 30 minutes before chemotherapy. Oral: Taken approx 1 hour before chemotherapy.
Adults (Postoperative) IV: 0.075 mg Infused over 10 seconds immediately before anesthesia induction.
Pediatrics (1 month to < 17 years) IV: 20 micrograms/kg (max 1.5 mg) Infused over 15 minutes approx 30 minutes before chemotherapy.

Administration and Preparation Rules

  • Frequency: The medicine is intended as a single administration per chemotherapy course. Repeated dosing is generally not recommended within a seven-day interval for the IV formulation, or is limited to a single dose per course for the oral formulation.
  • Oral Capsule: May be taken with or without food.
  • IV Preparation: The injection is supplied ready for use and must not be mixed with other drugs. The IV line should be flushed with normal saline both before and after administration.
  • Handling: Before use, the solution must be visually inspected for particulate matter or discoloration. Any unused portion of the single-dose vial or pre-filled syringe must be discarded. No dosage adjustment is necessary for elderly patients or those with renal or hepatic impairment.

Recent Clinical Evidence

Research evidence: Overview of Studies for Paloxi

The research for Palonosetron (Paloxi) primarily involves randomized controlled trials (RCTs) and systematic reviews, which are study types often used in regulatory evaluation. These studies help show what has been observed so far about the drug’s use in specific clinical settings, particularly for conditions characterized by episodic or acute changes. The research describes group patterns, not personal outcomes.


Research related to Chemotherapy-Induced Nausea and Vomiting (CINV)

Research has extensively evaluated Palonosetron in the context of CINV. Studies evaluated in patients receiving both Moderately Emetogenic Chemotherapy (MEC) and Highly Emetogenic Chemotherapy (HEC) regimens. The primary outcome measured in these trials was the proportion of patients who achieved a Complete Response—meaning no vomiting or retching and no need for rescue antiemetic medication.

For patients receiving MEC, the research explored whether Palonosetron-based regimens varied in outcomes when compared to certain older 5-HT3 antagonists. Studies reported patterns observed in the trials, and research has explored whether the drug may be associated with differences in outcomes related to sickness that happens immediately after chemotherapy and sickness that is delayed for several days afterward. In the setting of HEC, a regimen involving the medication was observed in combination with other antiemetics as part of the standard care approach.


Research related to Postoperative Nausea and Vomiting (PONV)

Palonosetron was studied for its application in PONV. These trials primarily consisted of RCTs and systematic reviews that included adult patients undergoing various surgical procedures. The studies monitored outcomes related to physical discomfort, specifically the incidence of nausea and vomiting, over follow-up durations that were typically limited to the first 24 to 48 hours post-surgery. Findings describe patterns observed in the studies where the prophylactic use of the drug was associated with differences in the incidence of vomiting during this short-term period.

Frequently Asked Questions (FAQ)

Common questions about Paloxi (FAQ)


Q: What does 'contraindicated' mean in relation to Paloxi?

According to official regulatory documents, Paloxi is contraindicated in patients who have a known hypersensitivity or allergy to the drug itself or to any of its components. In these situations, its use is generally avoided as a safety measure.


Q: What types of drug-drug interactions are commonly described for Paloxi?

Official documents discuss a potential for a rare but serious condition called Serotonin Syndrome when Paloxi is used with certain other serotonergic medicines, such as specific drugs for depression (SSRIs or SNRIs) or migraine. The product label specifically advises caution when Paloxi is combined with other medicines that affect the serotonin system or heart rhythm.


Q: Can Paloxi be taken with over-the-counter cold medicines?

Official patient counseling information advises patients to inform their healthcare provider about all medicines they are taking, which includes over-the-counter cold medicines. This is because some common cold remedies can affect the serotonin system or heart rhythm, which are areas of caution noted in the regulatory product information.


Q: Is it okay to take Paloxi if I also take a vitamin supplement?

Official patient counseling information advises reporting all supplements and medications, including vitamins and herbal products, to your healthcare provider. This allows the provider to assess the full treatment plan and check for any potential interactions that may need monitoring.


Q: What are the most common side effects reported by people taking Paloxi?

Official data from adult clinical trials for chemotherapy-induced nausea and vomiting indicate that the most common adverse reactions reported (with an incidence of 5% or more) are headache and constipation.


Q: Is it normal to feel tired or dizzy when first starting Paloxi?

Official data lists both dizziness and fatigue (tiredness) as adverse reactions observed in clinical trials. While they were generally reported with a lower incidence than headache or constipation, they are documented potential effects of the medicine.


Q: Can Paloxi affect sleep patterns?

Official adverse reaction data includes reports of insomnia (difficulty sleeping) and somnolence (drowsiness) in clinical trials. These effects were generally reported with a low incidence, but they are noted potential effects of the drug.


Q: Is Paloxi considered a long-term or short-term treatment?

Paloxi is intended for use as a single administration for each course of chemotherapy or surgical procedure. Regulatory documentation defines its use as an acute, preventative measure, not a daily, long-term treatment.


Q: What should I do if the side effects of Paloxi feel too severe?

Official patient information advises patients to seek medical advice from a healthcare professional about side effects. Furthermore, if you experience signs of a severe allergic reaction or the rare Serotonin Syndrome, the regulatory information recommends seeking immediate medical attention.


Q: What are the contraindications listed for Paloxi?

Official regulatory documents state that the drug is contraindicated in patients with known hypersensitivity to Paloxi or any of its components. This means use is generally avoided if a patient has a confirmed allergy to the medicine.


Q: Does Paloxi require any special monitoring while I am taking it?

The official product information notes that patients may be monitored for the emergence of Serotonin Syndrome, especially if the drug is used with other serotonergic medicines. Additionally, patients with certain heart problems or electrolyte imbalances may require specific monitoring by a healthcare professional.


Q: Are there any restrictions on driving or operating machinery while on Paloxi?

Official documentation advises caution regarding driving or operating machinery. This caution is based on the potential for the drug to cause side effects such as dizziness, somnolence (drowsiness), or fatigue.


Q: What is the risk of a severe allergic reaction to Paloxi?

Regulatory information indicates that hypersensitivity reactions, including anaphylaxis (a severe, life-threatening allergic reaction), have been reported with this class of 5-HT3 receptor antagonists. If signs of a severe allergic reaction occur, immediate medical attention is necessary.


Q: Can Paloxi cause changes in mood or behavior?

The official warning for Serotonin Syndrome lists mental status changes—such as agitation, hallucinations, and delirium—as potential signs of this rare condition. This risk is primarily associated with the concomitant use of other serotonergic drugs.


Q: Is it possible for Paloxi to interact with herbal supplements like St. John's Wort?

Official patient counseling information advises reporting all medications and supplements, including herbal products, to your healthcare provider. St. John's Wort is sometimes described as a serotonergic agent, which the product label lists as a general caution for interaction.


Q: Is Paloxi approved in countries outside of the US?

Yes, official documents from regulatory bodies like the European Medicines Agency (EMA) and others indicate that Paloxi (or a drug containing palonosetron) is authorized for use in regions outside of the US.


Q: Is Paloxi safe to use during pregnancy or while breastfeeding?

For pregnancy, there are limited human data, and regulatory documents indicate use is generally reserved for situations where the potential benefit justifies the potential risk. For breastfeeding, it is unknown if the drug is passed into human milk; the official advice requires a decision between discontinuing nursing or discontinuing the drug.


Q: Does Paloxi affect fertility?

Nonclinical animal studies that examined the drug's effects indicated no adverse impact on fertility or general reproductive performance.


Q: Is it common to experience dry mouth with Paloxi?

Official adverse reaction data includes reports of dry mouth (xerostomia). However, this event was generally reported with a low incidence (less than 1%) in clinical trials.


Q: Can I use Paloxi if I have a history of heart problems?

Official product information describes the need for caution for patients with a history of QT prolongation, certain heart problems (like congestive heart failure), or electrolyte abnormalities. This is due to a risk of potential effects on heart rhythm.


Q: Is Paloxi a controlled substance?

According to regulatory scheduling bodies, Paloxi is not classified as a controlled substance under the US Controlled Substances Act.


Q: Are there any long-term side effects associated with Paloxi use?

Paloxi is intended for single-dose use as a preventative measure. The adverse event data reported on the label is generally collected from trials associated with this acute, short-term use.


Q: What is the relationship between Paloxi and existing mental health conditions?

The official label notes a potential risk of Serotonin Syndrome, which involves mental status changes and agitation. This risk is relevant for patients also taking other medicines that increase serotonin levels, which may include certain medications used to treat mental health conditions.


Q: Is there a maximum time a person should take Paloxi?

The official product information specifies that the drug is intended for single-dose administration for each course of chemotherapy or procedure. Repeat dosing of the IV formulation is generally not recommended within a seven-day interval.


Q: Where can I find the official patient information leaflet for Paloxi?

The official documentation advises patients to read the FDA-approved patient labeling or similar regulatory documents provided by the manufacturer. You can also ask your doctor or pharmacist for a copy of the official information written for health professionals.


Q: Is Paloxi described as being a cure for a condition?

No. The official indication states that Paloxi is used for the prevention of acute and delayed nausea and vomiting associated with chemotherapy or prevention of postoperative nausea and vomiting. Its function is preventative, not curative.

How should Paloxi be stored and disposed of?

How to Store and Dispose of Paloxi

Official regulatory documents define specific, non-advisory requirements for the storage and disposal of Paloxi (palonosetron).

Official Storage and Stability Requirements

Requirement Status
Temperature (Unopened Vial) Does not require any special temperature storage conditions.
In-Use Stability Use immediately upon opening of the vial.
Protection from Light No special precautions for protection from light are documented.
Container Must be stored in its original Type I glass vial.

Disposal and Environmental Mandates

Paloxi is intended for single use only. Any solution remaining in the vial after use must be discarded. The product is classified with the mandatory instruction to avoid release to the environment, requiring proper disposal through authorized pharmaceutical waste channels rather than household trash or wastewater systems. There are no special child-protection storage requirements listed beyond standard medicine practice.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Paloxi found in:

A-Z Index: